Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Intrahepatic cholangiocarcinoma (iCCA) is a malignant tumor originating within the intrahepatic bile ducts and is a form of bile duct cancer. According to Yaqoob Muhammad et al. (2026), iCCA ranks as the second most common primary liver cancer, accounting for approximately 20% of cases. According to Expert Market Research, cholangiocarcinoma incidence globally is rising, driven by increasing disease burden, improved diagnostic capabilities, and greater recognition of associated risk factors.

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

Intrahepatic Cholangiocarcinoma – Number of Cases by Year

Read more about this report - Request a Free Sample

Intrahepatic Cholangiocarcinoma Epidemiology Forecast Report Coverage

Expert Market Research's “Intrahepatic Cholangiocarcinoma Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of intrahepatic cholangiocarcinoma. It projects the future incidence and prevalence rates of intrahepatic cholangiocarcinoma cases across various populations. The study covers age, gender, and type as major determinants of the intrahepatic cholangiocarcinoma population. The report highlights patterns in the prevalence of intrahepatic cholangiocarcinoma over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of intrahepatic cholangiocarcinoma in the 8 major markets.

Regions Covered

  • United States
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Intrahepatic Cholangiocarcinoma Understanding: Disease Overview

Intrahepatic cholangiocarcinoma (iCCA) is a malignant tumor arising from the epithelial cells of the intrahepatic bile ducts within the liver. It develops when genetic and molecular alterations disrupt normal biliary cell growth, resulting in uncontrolled proliferation and tumor formation. iCCA is anatomically distinct from extrahepatic cholangiocarcinoma and is generally classified according to its histologic and molecular characteristics. Histologically, the major patterns include small-duct and large-duct types, which differ in their associated risk factors and molecular profiles. Bile duct cancer can remain asymptomatic during early stages, contributing to diagnosis at advanced disease stages.

Key Report Insights

Parameter

Insight

Largest Patient Pool

United States

Fastest Growing Country

India

High-Risk Population

Older adults and individuals with chronic biliary tract disease

Key Diagnostic Method

Contrast-enhanced magnetic resonance imaging and computed tomography, supported by tissue diagnosis

Major Risk Factor

Primary sclerosing cholangitis, hepatolithiasis, and chronic biliary inflammation

Major gap in the market

Late diagnosis and limited availability of effective curative treatment for advanced disease

Intrahepatic Cholangiocarcinoma Epidemiology Perspective

The intrahepatic cholangiocarcinoma epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the intrahepatic cholangiocarcinoma epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for intrahepatic cholangiocarcinoma and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

Intrahepatic cholangiocarcinoma represents approximately 10%–15% of primary hepatic malignancies and is the second most common primary liver cancer. According to Yaqoob Muhammad et al. (2026), it accounts for about 20% of primary liver cancer cases, with global incidence increasing over the past four decades.

Gender-Specific Cases of the Disease

Gender differences are observed in cholangiocarcinoma epidemiology. According to Jianguo Chen et al. (2026), the 2024 age-adjusted mortality rate was higher among men than women at 3.70 versus 3.11 per 100,000, respectively, although mortality increased faster among women.

Age-Specific Cases of the Disease

Intrahepatic cholangiocarcinoma predominantly affects older adults. According to François Ghiringhelli et al. (2023), half of biliary tract cancer patients were older than 75 years at diagnosis. Jianguo Chen et al. (2026) reported the highest crude mortality among adults aged 85 years or older.

Ethnicity-Wise Cases of the Disease

Ethnic differences have been reported in mortality patterns. As per Jianguo Chen et al. (2026), Hispanic individuals had the highest age-adjusted mortality rate at 3.47 per 100,000, while non-Hispanic Black individuals had the largest annual percentage increase at 4.03%.

Mortality and Survival Analysis of the Disease

Mortality has increased substantially over time. According to Jianguo Chen et al. (2026), annual deaths increased from 2,552 in 1999 to 9,752 in 2024, while the age-adjusted mortality rate increased from 1.44 to 3.35 per 100,000. Yaqoob Muhammad et al. (2026) reported five-year survival below 10%.

Type-Specific Disease Burden and Epidemiology Analysis

Disease Type

Prevalence

Small-Duct Type Intrahepatic Cholangiocarcinoma

Small-duct type iCCA is one of the two principal anatomical subtypes and arises from smaller intrahepatic bile ducts. Its epidemiological assessment is relevant to understanding differences in disease distribution and burden within intrahepatic cholangiocarcinoma.

Large-Duct Type Intrahepatic Cholangiocarcinoma

Large-duct type iCCA represents the second major anatomical subtype and originates from larger intrahepatic bile ducts. Epidemiological assessment of this subtype contributes to understanding the heterogeneity of intrahepatic cholangiocarcinoma and its distribution across patient populations.

Intrahepatic Cholangiocarcinoma – Number of Cases by Country

Read more about this report - Request a Free Sample

Country-wise Intrahepatic Cholangiocarcinoma Epidemiology

The intrahepatic cholangiocarcinoma epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country

Key Insights

United States

The United States has experienced a substantial increase in the intrahepatic cholangiocarcinoma burden. According to the National Organization for Rare Disorders, approximately 6,000 intrahepatic cholangiocarcinoma cases are diagnosed annually, with an incidence of approximately 1.49 per 100,000 people. According to Jianguo Chen et al. (2026), annual deaths increased from 2,552 in 1999 to 9,752 in 2024, accompanied by a rise in the age-adjusted mortality rate.

Germany

The epidemiological profile in Germany is influenced by the concentration of biliary tract cancer among older populations. According to François Ghiringhelli et al. (2023), half of biliary tract cancer patients were older than 75 years at diagnosis, highlighting the importance of advanced age in the observed disease burden.

France

France demonstrates a substantial intrahepatic component within the biliary tract cancer burden.

Italy

The epidemiological burden in Italy is shaped by the age distribution of biliary tract cancer. A significant share of biliary tract cancer patients are older than 75 years at diagnosis, supporting the importance of the aging population in the epidemiological profile of these malignancies.

Spain

Epidemiological patterns in Spain can be considered in the context of documented sex and age differences in biliary tract cancer. Cholangiocarcinoma mortality is higher among men globally, while an increasing burden of biliary tract cancer among younger adults has been observed across several geographic regions.

United Kingdom

Epidemiological patterns in the United Kingdom reflect the broader sex- and age-related characteristics of biliary tract malignancies. According to Jiao Su et al. (2024), cholangiocarcinoma mortality is higher among men than women globally, while the increasing burden of biliary tract cancer among younger adults has also been reported across different geographic regions.

Japan

Japan has a notable intrahepatic cholangiocarcinoma burden within Asia. According to Masashi Mizumoto et al. (2023), age-adjusted prevalence was 1.25 per 100,000 person-years among men and 0.77 per 100,000 person-years among women, indicating a higher reported burden among men.

India

India contributes to the epidemiological burden of biliary tract malignancies in Asia. According to Masashi Mizumoto et al. (2023), intrahepatic cholangiocarcinoma prevalence is high in Asia. Jiao Su et al. (2024) further reported geographic variation in biliary tract cancer burden, supporting the relevance of regional differences in epidemiological patterns.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

The regional disease epidemiology landscape for intrahepatic cholangiocarcinoma is characterized by substantial challenges in early detection, accurate diagnosis, and identification of actionable molecular alterations. Limited disease-specific symptoms often result in diagnosis at advanced stages, reducing opportunities for curative surgery. Molecular profiling represents an important emerging opportunity because identifying actionable alterations can support the selection of targeted therapies in eligible patients. Expanding access to specialized hepatobiliary imaging, pathology, and comprehensive genomic testing may improve diagnostic characterization across the United States, Europe, Japan, and India. Continued development of earlier detection strategies also represents an important unmet need.

Intrahepatic Cholangiocarcinoma: Treatment Overview

Intrahepatic cholangiocarcinoma treatment depends on tumor stage, anatomical location, resectability, molecular characteristics, and the patient's overall health. Surgical resection with curative intent is the primary treatment for localized, resectable disease. For unresectable or advanced disease, systemic therapy is commonly used, including platinum-based chemotherapy combined with gemcitabine and, where appropriate, immunotherapy. Targeted therapies may be considered when actionable alterations, such as fibroblast growth factor receptor 2 fusions or isocitrate dehydrogenase mutations, are identified. Cholangiocarcinoma treatment may also incorporate radiation therapy, locoregional approaches, and palliative care to manage symptoms and disease progression.

Key Questions Answered

  • What is the current and projected burden of intrahepatic cholangiocarcinoma across the 8 major markets?
  • Which countries across the 8 major markets account for the highest intrahepatic cholangiocarcinoma patient populations and fastest growth rates?
  • What is the diagnosed versus undiagnosed patient population of intrahepatic cholangiocarcinoma across key countries in the 8 major markets?
  • Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of intrahepatic cholangiocarcinoma across the 8 major markets?
  • What are the major drivers contributing to the increasing burden of intrahepatic cholangiocarcinoma across the 8 major markets?
  • How do major comorbidities and risk factors influence intrahepatic cholangiocarcinoma epidemiology trends across the 8 major markets?
  • What are the regional trends in advanced disease progression, treatment uptake, and patient management of intrahepatic cholangiocarcinoma across the 8 major markets?
  • Which patient segments represent the highest unmet clinical need in the intrahepatic cholangiocarcinoma landscape across the 8 major markets?
  • Which therapeutic areas linked to intrahepatic cholangiocarcinoma are expected to witness the strongest growth opportunities across the 8 major markets?
  • How is the intrahepatic cholangiocarcinoma epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
  • Which countries across the 8 major markets offer the most attractive market opportunities based on intrahepatic cholangiocarcinoma epidemiology and healthcare infrastructure?
  • Which epidemiological trends are expected to influence future drug development and market access strategies for intrahepatic cholangiocarcinoma across the 8 major markets?

Scope of the Intrahepatic Cholangiocarcinoma Epidemiology Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of intrahepatic cholangiocarcinoma based on several factors.
  • Intrahepatic Cholangiocarcinoma Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The intrahepatic cholangiocarcinoma report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Cholangiocarcinoma (CCA) Epidemiology Forecast

Cholangiocarcinoma Pipeline Analysis

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Report Features

Details

Base Year

2025

Historical Period

2019-2025

Forecast Period

2026-2035

Epidemiology Statistics Provided

  • Diagnosed Prevalent Cases
  • Type-Specific Cases
  • Gender-Specific Cases
  • Age-Specific Cases

Segmentation Provided

  • Epidemiology by Age Group
  • Epidemiology by Gender
  • Epidemiology by Type of Disease
  • Epidemiology by Region

Geographies Covered

  • United States
  • Germany
  • Italy
  • France
  • Spain
  • United Kingdom
  • Japan
  • India

Datasheet

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Datasheet

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us